The Effect of Central Injection of Ghrelin and Bombesin on Mean Plasma Thyroid Hormones Concentration

Fariba Mahmoudi\textsuperscript{a*}, Fatemeh Mohsennezhad\textsuperscript{b}, Homayoun Khazali\textsuperscript{c} and Haleh Ehtesham\textsuperscript{d}

\textsuperscript{a}Physiology Faculty, Payame Noor University, East Azarbaijan, Malekan Center, Iran. \textsuperscript{b}Physiology Faculty, Payame Noor University, Azarbijan Shargi, Malekan Center, Iran. \textsuperscript{c}Physiology Faculty, Shahid Beheshti University, Tehran, Iran. \textsuperscript{d}Biology Faculty, Payame Noor University, Iran.

Abstract

Ghrelin increases food intakes and body weight. Bombesin decreases food intakes and inhibits the stimulatory effect of Ghrelin on food intakes. Thyroid hormones have a crucial role in the regulation of body weight and yet the effect of bombesin on thyroid axis activity is not fully clear. Therefore, the goal of this study was to determine the effect of different doses of Ghrelin or bombesin on mean plasma thyroid-stimulating hormone (TSH), Triiodothyronine (T\textsubscript{3}) and Thyroxin (T\textsubscript{4}) concentration and also, the effect of interaction between Ghrelin and bombesin on thyroid axis activity.

Forty-nine rats in seven groups received saline or different doses of Ghrelin (4, 10 or 15 nmol) and bombesin (2.5, 5 or 10 nmol) and forty-two rats in six groups received simultaneous injection of Ghrelin (10 or 15 nmol) and different doses of bombesin (2.5, 5 or 10 nmol) via lateral cerebral ventricle. Blood samples were collected via decapitation 20 min after the injection and plasma was assayed for plasma TSH, T\textsubscript{3} and T\textsubscript{4} concentration by Radioimmunoassay (RIA).

Ghrelin significantly decreased the concentration of mean plasma thyroid hormones compared to saline. Bombesin did not significantly increase thyroid hormones concentration compared to saline but bombesin blocked the inhibitory effect of Ghrelin on thyroid axis activity. Bombesin may be the antagonist of Ghrelin action.

Keywords: Ghrelin; Bombesin; TSH; Triiodothyronine; Thyroxin.

Introduction

Ghrelin, a novel 28-amino acid peptide with an \textit{n}-octanoyl modification on Ser 3, was identified in stomach as an endogenous ligand for Growth Hormone Secretagogues Receptor (GHSR-Ia) in 1999 (1, 2). Ghrelin is well recognized to have an important role in the maintenance of energy homeostasis. During fasting, Ghrelin is secreted by X/A-like cells of stomach, neurons of hypothalamus and other tissues (1-3). It increases growth hormone secretions (1), gastric empty and food intakes via GHSR-Ia (4-6). It is suggested that different peptides may interact with Ghrelin actions. Bombesin is thought to be one of these peptides (7).

Bombesin, a 14-amino acid peptide, was identified from the skin of a frog in 1970. Later, two mammalian bombesin-related peptides, Gastrin-releasing peptide (GRP) and Neurromedin B (NMB), were identified in different parts of...
were carried out as previously described (5, 6). The effect of bombesin on thyroid axis activity is not completely clear. Some studies have reported an increase (15) in thyroid hormones concentration after intra-cerebral ventricle (ICV) or intra-peritoneal (IP) injection of bombesin. Furthermore, some studies reported that bombesin didn’t change thyroid hormones concentration (16, 17). It has also been reported that bombesin acts as a Ghrelin antagonist and blocks the stimulatory effects of Ghrelin on gastric motility and food intakes (7).

Hypothalamic-pituitary-thyroid axis (HPT) plays an important role in the regulation of metabolism and energy homeostasis through thyroid hormones. It has been shown that different neural, hormonal and environmental factors interact to modulate thyroid hormone secretions. This study was designed to determine the effect of Ghrelin or bombesin on mean plasma thyroid-stimulating hormone (TSH), T₃ and T₄ concentration. We also designed to investigate whether bombesin acts as a Ghrelin action antagonist and might block the inhibitory effect of Ghrelin on thyroid axis activity.

**Experimental**

**Animals**

Male Wistar Rats (n = 91) weighing 200-250 g (provided by the Center of Neuroscience Research of Shahid Beheshti University) were housed individually in cages under controlled temperature (22 ± 2°C) and light (12 h light/dark cycle). They had free access to food and water all the time.

**ICV cannulation and injections**

Animal surgery procedures and handling were carried out as previously described (5, 6). Animals were anesthetized by IP injection of a mixture of Ketamine and xylazine (100 mg/Kg BW Ketamine + 15 mg/Kg BW xylazine, (Alfasan Company, Holland)). For ICV injections, animals were placed in a stereotaxic frame (Stoelting, USA) and 22-gauge stainless cannulae were implanted in the right lateral cerebral ventricle. The cannula tip was placed at anterior-posterior ~ - 0.8, Lateral ~ 1.6 and dorsalventral ~ 3.2 mm according to the coordinates of Paxinos and Watson Atlas. The cannula was secured to the skull with three stainless steel screws and dental cement. The animals were kept in individual cages and habituated by handling every day to minimize the stress of surgery. After one week recovery period, 4, 10 or 15 nmol of Ghrelin or 2.5, 5 or 10 nmol of bombesin (Ghrelin and bombesin provided by Ana Spec Company (Ana Spec, USA)) were dissolved in 5 µL of 0.9% saline. The peptides were injected by a 27-gauge stainless steel injector which connected to PE-20 tubing. At the end of the experiment, the animals were decapitated and the blood samples were collected 20 min after the injections. The dosage of the peptides and the time of blood sampling were chosen based on the previous experiments (5, 6, 15). Heparin was used in samples to prevent clotting. Blood samples immediately centrifuged for 10 min at 3500 rpm and the plasma stored at -20°C until TSH, T₃ and T₄ concentrations were assayed. The animals’ brains were removed and kept in formalin (10%) for two weeks. The proper ICV cannulae placement was confirmed histologically. Only those animals with properly-positioned cannulae were included in data analysis.

Initially, the effect of different doses of either Ghrelin or bombesin on thyroid axis activity was investigated. Forty-nine rats in 7 groups (in each group, n = 7) received simultaneous administration of Ghrelin (10 or 15 nmol) and bombesin (2.5, 5 or 10 nmol) in a volume of 5 µL during the early light phase (0800 h - 0900 h). Blood samples were collected by decapitation 20 min after injections. In each group, the mean plasma TSH, T₃ and T₄ concentration were measured.

**Hormone assays and statistical analysis**

Plasma TSH, T₃ and T₄ were measured by using TSH, T₃ and T₄ kits (Sahand Iran Company, Iran) and the method of a homologous double antibody radio-immunoassay (RIA). The results are presented as mean ± SEM The data were analyzed by unpaired t-test, ANOVA test followed by post hoc Least Significant Difference and SPSS software. In all cases, p < 0.05 was considered to be statistically significant.

**Results and Discussion**

The results have shown that Ghrelin significantly decreased mean plasma TSH, T₃ and T₄ concentration compared to saline. Ghrelin (4 nmol) did not significantly alter mean plasma thyroid hormones concentration compared to saline but Ghrelin (10 or 15 nmol) significantly decreased TSH, T₃ and T₄ compared to saline (Figures 1, 2 and 3). Also as it is shown in Table 1, different doses of bombesin increased the mean plasma TSH, T₃ and T₄ concentration compared to saline but this increase was not statistically significant (Table 1).

The results also showed that in comparison with saline, Ghrelin (2.5 nmol) does not abolish the inhibitory effect of bombesin on mean plasma TSH, T₃ and T₄. In contrast, bombesin (5 or 10 nmol) significantly blocked the inhibitory effect of Ghrelin on mean plasma TSH, T₃ and T₄ compared to saline (Figures 1, 2 and 3). The results of this study showed that ICV injection of bombesin didn’t significantly alter
The thyroid hormone concentration which is consistent with the previous studies (16, 17). Moreover, the results showed that Ghrelin significantly decreased the mean plasma TSH, T3, and T4 concentrations.

It seems that the significant fall in TSH, T3, and T4 concentrations after the infusion of Ghrelin was most likely due to the effect of Ghrelin on different peptides (like Agouti-related peptide (AgRP) or Neuropeptide Y (NPY)) in the arcuate nucleus (ARC) of hypothalamus. Previous studies have demonstrated that Ghrelin increases the synthesis of AgRP/NPY in ARC neurons (4-6). It is also established that AgRP/NPY-immunoreactive axons densely innervate the thyrotropin-releasing hormone (TRH) neurons in the paraventricular nucleus (PVN) of hypothalamus and the exogenous ICV or PVN infusion of AgRP or NPY markedly inhibits the H-P-T axis activity (18-21). So, Ghrelin may have an inhibitory effect on thyroid axis activity via increasing AgRP or NPY.

Furthermore, it has been found that AgRP acts as an endogenous antagonist or inverse agonist at melanocortin receptors including MC4 and MC3 receptors on TRH neurons. The studies have shown that α-melanocyte-stimulating hormone (αMSH) neurons of ARC densely innervate the TRH neurons of PVN and there is a significantly increase in TSH and thyroid hormones level after ICV or PVN injection of αMSH (18, 22, 23). Therefore, we could expect that inhibitory activity of Ghrelin on hypothalamic-pituitary-thyroid (HPT) axis, at least partially, may due to an increase in the AgRP level and its antagonist action on αMSH receptors. It has been suggested that central Ghrelin blocked the GABA release from AgRP or NPY neurons of hypothalamus. The inhibition of GABA release is involved in the activation of CRF neurons and the increasing in corticotropin releasing hormone (CRH) from hypothalamus. (24). As the CRH and cortisol exert an inhibitory effect on plasma TSH, T3, and T4 concentrations (25, 26), the inhibitory effect of Ghrelin on thyroid axis may be partially due to the stimulatory effect of it on hypothalamic-pituitary-adrenal (HPA) axis.

In the present study, the effect of interaction between Ghrelin and bombesin on thyroid axis activity was investigated for the first time. The results demonstrated that bombesin significantly blocked the inhibitory effect of Ghrelin on mean plasma T3 and T4 concentrations. (2)

The effect of different doses of Ghrelin (Gr) and the effect of simultaneous administration of Gr and different doses of bombesin (B) on mean plasma T3 and T4 concentration were investigated. The effect of different doses of Ghrelin (Gr) and the effect of simultaneous administration of Gr and different doses of bombesin (B) on mean plasma T3 compared to saline (p < 0.05).

In comparison with saline, Ghrelin (10 or 15 nmol) significantly decreased the mean plasma TSH concentration. In comparison with saline, Ghrelin (10 or 15 nmol) significantly decreased the mean plasma T3 concentration and Bombesin (5 or 10 nmol) significantly blocked the inhibitory effect of Ghrelin on mean plasma T3 (p < 0.05).

**Conclusion**

Ghrelin significantly decreased the mean plasma TSH, T3, and T4 concentrations and bombesin blocks the inhibitory effect of Ghrelin on thyroid axis activity. The results suggested that bombesin may be the antagonist of Ghrelin action.

**Acknowledgment**

We really appreciate Mr. Ghaffari’s help from Shahid Beheshti University of Tehran.

**References**

(1) Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H and Kangawa K. Ghrelin is a growth hormone-releasing isolated peptide from stomach. Nature (1999) 402: 656-60.

(2) Kojima M and Kangawa K. Ghrelin: structure and function. Physiol. Rev. (2005) 85: 495-522.

(3) Gaytan F, Morales C, Barreiro ML, Jeffery P, Chopin LK, Herington AC, Casanueva FF, Aguilar E, Dieguez C and Tena-Sempere M. Expression of growth hormone secretagogue receptor type 1a, the functional Ghrelin receptor, in human ovarian surface epithelium, Mullerian duct derivatives, and ovarian tumors. J. Clin. Endocrinol. Metab. (2005) 90: 1798-804.

(4) Kamigori J, Tamura H, Shinizu T, Sugihara H and Wakabayashi I. Chronic central infusion of Ghrelin increases hypothalamic neuropeptide Y and agouti-related protein mRNA levels and body weight in rats. Diabetes (2001) 50: 2438-43.

(5) Wren AM, Small CJ, Ward HL, Murphy KG, Dakin CL, Taheri S, Kennedy AR, Roberts GR, Morgan DG, Ghatei MA and Bloom SR. The novel hypothalamic peptide Ghrelin stimulates food intake and growth hormone secretion. Endocrinology (2000) 141: 4325-4328.

(6) Wren AM, Small CJ, Abbott CR, Dhillon WS, Seal LJ, Cohen MA, Barterian RL, Taheri S, Stanley SA, Ghatei MA and Bloom SR. Ghrelin causes hyperphagia and obesity in rats. Diabetes (2001) 50: 2540-7.

(7) Koblet P, Goebel M, Stengel A, Schmidtmann M, van der Voort IR, Tebbe JH, Vah RW, Klupp BF, Wiedenmann B, Wang L, Taché Y and Mönnikes H. Bombesin, but not amylin, blocks the orexigenic effect of peripheral Ghrelin. Am. J. Physiol. Regul. Integr. Comp. Physiol. (2006) 291: R903-13.

(8) Merdi Z, McIntosh J and Austin H. Role of bombesin-related peptides in the control of food intake. Neuropeptides (1999) 33: 376-86.

(9) Haminick BA and Peter RE. Bombesin acts to suppress feeding behavior and alter serum growth hormone in goldfish. Physiol. Behav. (1994) 55: 65-72.

(10) Koblet P, Tebbe JH, Tjandra I, Stengel A, Bae HG, Andreassen V, van der Voort IR, Vah RW, Wener CH, Klupp BF, Wiedenmann B, Wang L, Taché Y and Mönnikes H. CCK inhibits the orexigenic effect of peripheral Ghrelin. Am. J. Physiol. Regul. Integr. Comp. Physiol. (2005) 288: R751-8.
Porreca F, Burks TF and Koslo RJ. Centrally-mediated bombesin effects on gastrointestinal motility. *Life Sci.* (1985) 37: 125-34.

Flynn FW and Robillard L. Inhibition of ingestive behavior following fourth ventricle bombesin injection in chronic decerebrate rats. *Am. J. Physiol. Regul. Integr. Comp. Physiol.* (1992) 10: 1014.

Motamedi F, Rashidy-Pour A, Zarrindast MR and Badavi M. Bombesin-induced anorexia requires central bombesin receptor activation: independence from interaction with central catecholaminergic systems. *Psychopharmacology* (1993) 110: 193-7.

Kent P, Plamondon H and Merali Z. Pharmacoc-ontogeny of bombesin›s suppression of food intake and its attenuation by histamine H₁ receptor agonists. *Develop. Brain Res.* (1997) 102: 87-95.

Baranowska B, Wolińska-Witort E, Chmielowska M, Martyńska L, Baranowska-Bik A and Bik W. The role of bombesin in the mechanism of pituitary hormones release. *Neuro. Endocrinol. Lett.* (2005) 26: 463-7.

Malendowicz LK and Miśkowiak B. Effects of prolonged administration of neurotensin, arginine-vasopressin, NPY, and bombesin on blood TSH, T₃ and T₄ levels in the rat. *In-vivo.* (1990) 4: 259-61.

Pontiroli AEi and Scarpignato C. Effect of Bombesin on Basal and Stimulated Secretion of Some Pituitary Hormones in Humans. *Horm. Res.* (1986) 23: 129-35.

Fekete C, Kelly J, Mihály E, Sarkar S, Rand WM, Légrádi G, Emerson CH and Lechan RM. Neuropeptide Y has a central inhibitory action on the hypothalamus-Pituitary- Thyroid axis. *Endocrinology.* (2001) 142: 2606-13.

Fekete C, Kelly J, Mihály E, Sarkar S, Rand WM, Légrádi G, Emerson CH and Lechan RM. Agouti-Related Protein (AgRP) has a central inhibitory action on the hypothalamus- Pituitary- Thyroid (HPT) axis; Comparisons between the effect of AgRP and Neuropeptide Y on energy homeostasis and the HPT axis. *Endocrinology.* (2002) 143: 3846-53.

Kawano H and Masuko S. Beta- endorphin adrenocorticotrophic hormone and neuropeptide Y- containing projection fibers from the arcuate hypothalamic nucleus make synaptic contacts on to nucleus preopticus medianus neurons projecting to the paraventricular hypothalamic nucleus in the rat. *Neuro Sci.* (2000) 98: 555-65.

Legradi G and Lechan RM. Agouri-Related protein containing nerve terminals innervate thyrotropin releasing hormone neurons in the hypothalamic paraventricular nucleus. *Endocrinology.* (1999) 140: 3643-52.

Fekete C, Légrádi G, Mihály E, Huang QH, Tatro JB, Rand WM, Emerson CH and Lechan RM. Alphamelanocyte- stimulating hormone is contained in nerve terminals innervating thyrotropin- releasing hormone- synthesizing neurons in the hypothalamic paraventricular nucleus and prevents fasting- induced suppression of prothyrotropin- releasing hormone gene expression. *J. Neuro. Sci.* (2000) 20: 1550-58.

Fekete C, Marks DL, Sarkar S, Emerson CH, Rand WM, Cone RD and Lechan RM. Effect of Agouti-Related Protein in regulation of the hypothalamic-pituitary-thyroid axis in the melanocortin receptor knockout mouse. *Endocrinology.* (2004) 145: 4816-21.

Cowley MA, Smith RG, Diano S, Tschöp M, Pronchuk N, Grove KL, Strasburger CJ, Bidlingmaier M, Esterman M, Heiman ML, Garcia-Segura LM, Nilnini EA, Mendez P, Low MJ, Sotonyi P, Friedman JM, Liu H, Pinto S, Colmers WF, Cone RD and Horvath TL. The distribution and mechanism of action of ghrelin in the CNS demonstrates a novel hypothalamic circuit regulating energy homeostasis. *Neuroendocrinology.* (2001) 73: 203-14.

Giordano R, Picu A, Broglio F, Bonelli L, Baldi M, Berardelli R, Ghigo E and Arvat E. Ghrelin, hypothalamus- Pituitary- Adrenal axis and cushing’s syndrome. *Pituitary.* (2004) 7: 243-38.

Jaszberényi M, Bujdosó E, Bagosi Z and Telegdy G. Mediation of the behavioral, endocrine and thermoregulatory actions of ghrelin. *Horm Behave.* (2006) 50: 266-73.

This article is available online at http://www.ijpr.ir